What is the Project Incubator Program?

The Medicines Intelligence Centre of Research Excellence (MI-CRE) aims to deliver a coordinated research program that accelerates the development and translation of evidence about real-world medicine use and outcomes, leading to major improvements in the quality use of medicines and reductions in medicine-related harm.

MI-CRE achieves this by simultaneously: (i) generating timely real world evidence about medicine use and outcomes; (ii) identifying, triaging and responding to priority questions and breaking down barriers to research translation by fostering engagement with policy makers and other end-users; and (iii) equipping the next generation of medicines researchers in Australia with the skills to co-create evidence with ‘medicines intelligence’ end-users.

The MI-CRE Project Incubator initiative incorporates all three of these actions to deliver on the MI-CRE vision. Specifically, the initiative provides a structured opportunity for early- and mid-career medicines intelligence researchers to obtain end-user input from project inception and throughout its lifecycle.

MI-CRE researchers applying for funding through the MI-CRE Project Incubator Program present their research proposals to a panel of internal and external stakeholders, including other MI-CRE members, potential collaborators, consumers, government representatives (including TGA and PBAC), and industry experts to further develop their project ideas and also generate new ones. The Incubator Program also ensures that MI-CRE funded or initiated projects are aligned with our aims and expectations, including building in a knowledge translation plan and early engagement with end-users. The presentation sessions are held throughout the year (face-to-face where possible) and are designed to incubate ideas and support creative thinking and great research!

Below we have showcased the projects underway through the MI-CRE Project Incubator Program and will provide regular updates on the impact generated throughout their lifecycle.

Initiation and long-term use of opioids after hospitalisation 

Project Lead: Malcolm Gillies

Trying some new toppings on PAVLOVA

Project Lead: Jacques Raubenheimer

Application of TreeScan for monitoring adverse drug events in the Australian setting

Project Lead: Jack Janetzki

Equity in use of medicines and healthcare: Towards greater protection for the vulnerable

Project Leads: Serena Yu, Peyman Firouzi-Naeim

Janus kinase inhibitors (JAKi) and cardiovascular risks among patients with inflammatory disease in Australia

Project Lead: Claire Deakin 

Utilisation of tapentadol in Australia

Project Lead: Ximena Camacho

Co-designing a consumer-focused digital health platform to improve adverse drug event (ADE) detection, management and reporting

Project Lead: Renly Lim

Association between long-term medication use and ageing

Project Lead: Erin Kelty

Scoping review of data and methods used in studies that estimated Covid-19 vaccine effectiveness in reducing cause-specific and all-cause mortality during the SARS-CoV-2 pandemic

Project Lead: Paulina Stehlik

Psychotropic Medicine Use Preceding Deliberate Self-poisoning: A Data Linkage Study

Project Lead: Firouzeh Noghrehchi

Optimising best-practice use of cardiometabolic medicines in Australia using big data

Project Lead: Juliana de Oliveria Costa